pulmonari
complic
pc
hematolog
malign
hm
treatment
includ
hematopoiet
cell
transplant
hct
common
caus
morbid
mortal
despit
advanc
manag
patient
remain
highli
suscept
lung
injuri
involv
one
anatom
compart
lower
respiratori
tract
lrt
especi
lung
parenchyma
vulner
parenchym
pc
multifactori
determin
larg
type
magnitud
durat
impair
immun
defens
risk
compound
treatmentrel
toxic
complex
comorbid
recurr
nosocomi
exposur
patient
greatest
risk
infecti
pc
includ
prolong
neutropenia
recipi
hct
infecti
noninfecti
parenchym
pc
occur
allogen
hct
patient
autolog
hct
frequent
acut
set
repres
common
caus
admiss
intens
care
unit
pc
significantli
increas
mortal
treatment
eg
induct
therapi
acut
leukemia
later
period
hct
predisposit
requir
clinic
vigil
formul
differenti
diagnosi
perform
prompt
diagnost
investig
initi
treatment
practic
specif
caus
pulmonari
diseas
frequent
undiagnos
ant
mortem
popul
elus
understand
diseas
mechan
notabl
inflammatori
hctrelat
pc
may
contribut
dispar
howev
lack
diagnosi
also
reflect
delay
altogeth
defer
diagnost
sampl
lrt
set
excess
patient
risk
andor
provid
prefer
suggest
diagnost
uncertainti
regard
pc
may
impact
mortal
hct
difficulti
obtain
time
diagnosi
natur
interfer
clinician
abil
target
treatment
lead
prolong
empir
manag
mani
pc
institut
broad
therapi
come
exposur
unnecessari
toxic
ripe
condit
emerg
antibiot
resist
possibl
acceler
poor
outcom
given
incid
acut
often
fatal
pc
highli
immunocompromis
popul
comprehens
approach
diagnost
evalu
pc
hm
hct
patient
essenti
integr
inform
regard
highrisk
host
featur
abnorm
chest
imag
pattern
noninvas
test
result
inform
decis
pursu
lung
sampl
via
minim
invas
techniqu
fiberopt
bronchoscopi
fob
modal
goal
paper
provid
overview
consider
practic
diagnost
approach
adult
hm
hct
patient
respiratori
sign
symptom
focu
investig
pc
involv
lung
parenchyma
initi
survey
clinic
landscap
essenti
ascertain
pc
risk
determin
subsequ
diagnost
step
time
present
host
characterist
immun
deficit
treatmentrel
factor
past
exposur
may
impact
riskbenefit
equat
lrt
sampl
hm
hct
patient
new
pulmonari
infiltr
chest
imag
identif
highrisk
featur
eg
prolong
neutropenia
known
mold
exposur
may
also
rais
suspicion
specif
diseas
entiti
eg
invas
fungal
infect
earli
enough
expedit
lung
sampl
initi
presumpt
therapi
understand
time
respiratori
symptom
onset
rel
immunosuppress
treatment
help
narrow
differenti
diagnosi
pc
defect
innat
cellmedi
humor
immun
well
splenic
defect
predispos
infect
specif
organ
tabl
neutropenia
common
individu
risk
factor
cancerrel
pneumonia
greater
risk
febril
neutropenia
fn
expect
specif
chemotherapi
regimen
mani
type
hm
underli
hm
may
also
exacerb
treatmentrel
deficit
cell
function
albeit
less
predict
recipi
hct
addit
treatmentrel
risk
factor
pc
includ
intens
condit
regimen
stem
cell
sourc
prolong
cytopenia
intensifi
immunosuppress
graftversushost
diseas
pretranspl
condit
confer
share
suscept
pc
engraft
fig
preengraft
pc
usual
infecti
occur
within
day
hct
commonli
includ
gramneg
bacteri
pneumonia
set
neutropenia
andor
mucos
earli
postengraft
pc
occur
day
typic
includ
infecti
process
associ
impair
cellular
immun
latepostengraft
pc
tend
develop
day
typic
immun
reconstitut
atyp
process
may
occur
outsid
expect
window
base
addit
host
risk
factor
eg
opportunist
infect
late
engraft
set
delay
antibodi
respons
pc
occur
engraft
predominantli
infecti
associ
significantli
lower
mortal
compar
develop
later
difficult
predict
time
noninfecti
pc
hct
spectrum
acut
lung
injuri
syndrom
may
parallel
endotheli
damag
occur
organ
site
eg
liver
earli
hct
preengraft
syndrom
diffus
alveolar
hemorrhag
develop
soon
allogen
autolog
hct
wherea
idiopath
pneumonia
syndrom
occur
somewhat
later
albeit
first
day
allogen
hct
although
process
variabl
steroid
respons
diffus
alveolar
hemorrhag
idiopath
pneumonia
syndrom
associ
high
mortal
mortal
preengraft
syndrom
tend
significantli
less
note
acut
respiratori
distress
syndrom
hct
subject
often
associ
infecti
etiolog
carri
high
mortal
set
invas
fungal
diseas
thu
earli
recognit
appropri
intervent
infecti
noninfecti
transplantrel
pc
imper
success
outcom
medic
histori
hm
hct
patient
among
complex
repres
uniqu
diseas
chronolog
treatment
coursesrespons
comorbid
histori
tobacco
smoke
condit
chronic
obstruct
pulmonari
diseas
predispos
lrt
colon
bacteri
pathogen
therebi
increas
risk
infecti
pc
develop
mucos
common
complic
myeloabl
chemotherapi
may
impair
airway
clearanc
nutrit
intak
therebi
increas
risk
pneumonia
bacterem
event
noninfecti
caus
pc
may
suggest
histori
pneumotox
chemotherapi
eg
bleomycin
alkyl
agent
radiat
therapi
noncancerrel
medic
eg
amiodaron
transfus
blood
product
histori
pulmonari
diseas
cardiac
dysfunct
may
increas
risk
drugrel
lung
toxic
influenc
acuiti
present
pretranspl
pulmonari
function
consid
assess
pc
risk
hct
particular
reduc
lung
function
measur
pulmonari
function
test
associ
sever
pc
occur
earli
hct
abnorm
diffus
lung
capac
carbon
monoxid
forc
expiratori
volum
second
also
contribut
hctcomorbid
index
valid
prognost
indic
posttranspl
mortal
ongo
investig
microbi
biomark
allogen
hct
recipi
suggest
chang
gut
flora
commonli
occur
within
day
initi
pretranspl
condit
antimicrobi
prophylaxi
may
increas
likelihood
develop
pc
may
occur
either
via
direct
transloc
infecti
agent
indirectli
via
stimul
aberr
pulmonari
inflammatori
respons
importantli
gut
microbiota
chang
pc
may
signific
independ
predictor
transplantrel
mortal
find
highlight
need
continu
develop
tool
identifi
atrisk
popul
although
mani
common
respiratori
tract
infect
aris
patient
microbi
flora
other
contract
exposur
sick
individu
environment
sourc
elicit
exposur
import
survey
landscap
potenti
infect
de
novo
eg
multidrugresist
organ
hospit
set
reactiv
latent
infect
patient
question
travel
resid
area
exposur
mycobacterium
tuberculosi
endem
fungal
organ
includ
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
other
inquiri
regard
exposur
hous
pet
bird
farm
anim
aerosol
water
sourc
disturb
soil
dust
provid
clue
infect
caus
divers
organ
nocardia
speci
spp
legionella
spp
toxoplasma
gondii
cryptococcu
neoforman
immunolog
evid
patient
donor
case
allogen
hct
histori
latent
infect
cytomegaloviru
epsteinbarr
viru
gondii
tuberculosi
need
review
care
exposur
kept
mind
consid
addit
noninvas
invas
diagnost
investig
pursu
beyond
routin
test
pc
broadli
categor
infecti
inflammatori
malign
fig
process
within
group
share
common
ident
base
predomin
pathophysiolog
although
overlap
epsteinbarr
virusrel
posttranspl
lymphoprolif
disord
presenc
abnorm
vital
sign
eg
fever
hypoxemia
respiratori
symptom
eg
dyspnea
cough
readili
distinguish
pc
process
whose
present
may
vari
underli
hm
exampl
hemoptysi
may
suggest
alveolar
hemorrhag
howev
absenc
common
diffus
alveolar
hemorrhag
hypoxemia
elev
alveolararteri
gradient
may
suggest
pneumocysti
jirovecii
pneumonia
etiolog
patchi
ground
glass
opac
chest
imag
investig
altern
explan
pulmonari
embol
may
requir
radiograph
find
seem
proport
ga
exchang
abnorm
acuiti
present
may
provid
addit
insight
differenti
diagnosi
appropri
context
exampl
acut
hypoxemia
new
crackl
set
blood
product
transfus
may
suggest
suggest
transfusionrel
acut
lung
injuri
transfusionassoci
circul
overload
howev
investig
pc
caus
indic
often
modal
chest
imag
gener
obtain
diagnosi
hm
pulmonari
manifest
work
suspici
sign
unexplain
fever
manag
latter
indic
common
hct
set
neutropenia
patient
fn
present
lung
infiltr
distribut
morpholog
infiltr
help
refin
pc
differenti
diagnosi
although
diminish
inflammatori
respons
may
alter
delay
appear
typic
find
signific
limit
sensit
chest
radiograph
diagnos
pc
hm
hct
patient
even
combin
clinic
data
studi
febril
immunocompromis
patient
onehalf
neg
chest
radiograph
parenchym
abnorm
detect
comput
tomographi
ct
imag
chest
thu
relianc
ct
imag
chest
initi
diagnost
imag
modal
commonplac
manag
compromis
host
respiratori
complaint
chest
ct
also
perform
routin
diseas
surveil
treatment
certain
hm
eg
lymphoma
may
use
comparison
diagnost
chest
radiograph
suggest
new
pc
special
role
highresolut
ct
consid
use
hm
hct
subgroup
howev
interpret
consid
unambigu
pet
scan
may
use
evalu
solitari
pulmonari
nodul
mri
may
requir
subject
receiv
iodin
contrast
ct
studi
although
noncontrast
ct
gener
suffici
evalu
parenchym
infiltr
abnorm
parenchym
pattern
tabl
show
differenti
diagnos
consid
hm
hct
patient
present
common
parenchym
pattern
chest
ct
includ
airspac
consolid
ground
glass
opac
nodul
reticular
chang
radiograph
find
may
typic
certain
clinic
scenario
exampl
symmetr
ground
glass
opac
sharp
margin
prior
radiat
field
suggest
radiat
pneumon
diffus
reticular
mark
leukem
blast
crisi
may
support
pulmonari
leukostasi
differenti
may
justifi
narrow
quickli
enough
warrant
empir
treatment
without
thorough
investig
select
case
howev
radiograph
abnorm
frequent
overlap
illdefin
manag
may
present
conflict
exampl
bacteri
fungal
pneumonia
often
present
focal
multifoc
airspac
consolid
noninfecti
organ
pneumonia
given
organ
pneumonia
would
requir
steroid
treatment
steroid
would
like
exacerb
infecti
process
investig
paramount
along
integr
inform
regard
underli
patient
risk
factor
clinic
present
abnorm
imag
result
noninvas
test
help
determin
next
step
manag
case
find
may
appar
chest
radiographi
chest
comput
tomographi
scan
especi
perform
high
resolut
allow
earlier
detect
common
radiolog
pattern
includ
airspac
consolid
groundglass
attenu
interstiti
infiltr
nodularmass
lesion
b
uniqu
hematopoiet
cell
transplant
recipi
infecti
workup
togeth
chest
imag
result
noninvas
diagnost
test
narrow
differenti
diagnosi
infecti
pc
fig
routin
microbiolog
serolog
investig
serum
urin
respiratori
specimen
nasopharyng
swab
sputum
tracheal
aspir
usual
obtain
time
clinic
present
addit
assay
request
base
risk
featur
patient
exampl
endem
fungal
exposur
chest
ct
pattern
exampl
nodul
infiltr
may
heighten
suspicion
atyp
process
recent
year
culturebas
method
pathogen
isol
respiratori
secret
blood
supplement
supplant
molecular
test
techniqu
polymeras
chain
reaction
diagnosi
infecti
pc
tabl
institut
polymeras
chain
reaction
identif
p
jirovecii
tuberculosi
communityacquir
respiratori
virus
perform
routin
respiratori
sampl
appropri
hm
hct
patient
antigen
test
serum
eg
aspergillu
galactomannan
betad
glucan
cryptococc
histoplasma
antigen
urin
eg
streptococcu
pneumonia
legionella
pneumophila
antigen
obtain
appropri
patient
case
neg
predict
valu
may
valuabl
betad
glucan
moder
diagnost
valu
mitig
high
neg
predict
valu
critic
ill
hm
patient
test
result
preexist
clinic
suspicion
essenti
interpret
avoid
overdiagnosi
underdiagnosi
ensur
appropri
treatment
decis
direct
stain
lack
atyp
organ
pneumonia
c
pneumonia
special
media
requir
cultur
l
pneumophila
cultur
unavail
p
jirovecii
fungi
difficult
cultiv
clinic
laboratori
viral
stain
cultur
predominantli
done
cmv
cultur
uncommonli
perform
identif
gondii
stercorali
b
multiplex
pcr
avail
comprehens
panel
respiratori
virus
atyp
bacteria
includ
l
pneumonia
c
pneumonia
pneumonia
b
pertussi
pcr
tuberculosi
routin
perform
sampl
posit
acidfast
stain
smearneg
specimen
highrisk
patient
c
cytolog
special
stain
gener
perform
identif
organ
difficult
cultiv
laboratori
includ
acidfast
bacteria
fungi
includ
pneumocysti
cmv
test
may
assist
microbiolog
diagnosi
includ
complement
fixat
cold
agglutinin
mycoplasma
serum
urin
antigen
test
pneumonia
l
pneumophilia
serotyp
nonbal
antigen
test
may
also
done
c
neoforman
serum
h
capsulatum
serum
urin
b
dermatitidi
serum
urin
well
hsv
rsv
influenza
b
adenoviru
serum
viral
load
provid
inform
pertain
cmv
activ
nasopharyng
swab
pcr
carv
may
use
bronchoscopi
serolog
peripher
cell
count
eg
eosinophilia
stool
studi
may
use
adjunct
test
parasit
caus
infect
notabl
strongyloid
limit
use
nonspecif
inflammatori
biomark
creactiv
protein
diagnos
pc
hm
hct
patient
lack
like
due
test
patient
characterist
includ
highli
vari
aberr
respons
inflamm
serum
procalcitonin
may
use
distinguish
bacteri
viral
fungal
infect
immunocompromis
host
may
consid
neg
predict
valu
neutropen
patient
persist
fever
gener
limit
specif
critic
ill
hm
patient
time
fn
onset
might
greatest
practic
use
furthermor
limit
studi
hct
recipi
suggest
procalcitonin
distinguish
infecti
noninfecti
pulmonari
process
may
indic
sever
empir
treatment
decis
like
made
alter
absenc
reliabl
support
data
lung
function
test
indic
commonli
evalu
new
pulmonari
infiltr
pulmonari
function
test
may
valuabl
suspicion
airway
diseas
bronchiol
obliteran
syndrom
late
complic
well
monitor
respons
therapi
common
problem
chemotherapi
toxic
last
echocardiographi
measur
serum
bnatriuret
peptid
may
help
distinguish
cardiogen
pulmonari
edema
caus
diffus
lung
infiltr
result
noninvas
test
may
support
specif
diagnosi
invas
aspergillosi
patient
fn
present
halo
sign
chest
ct
elev
serum
aspergillu
galactomannan
antigen
result
may
accept
driver
therapi
highrisk
unstabl
patient
safe
undergo
diagnost
workup
howev
clinic
stabl
patient
pauciti
data
support
probabl
caus
diagnost
fob
import
tool
consid
earli
pc
manag
purpos
prompt
lung
sampl
much
identifi
infecti
etiolog
base
modifi
antimicrobi
therapi
rule
infecti
process
empir
augment
immunosuppress
altern
caus
minim
invas
lung
sampl
via
fob
like
captur
snapshot
pulmonari
process
expector
sputum
tracheal
aspir
specimen
highli
contamin
colon
flora
may
provid
addit
diagnost
inform
onehalf
patient
visual
inspect
airway
may
identifi
area
focal
hemorrhag
fungal
plaqu
purul
tumor
specimen
may
collect
entir
lrt
via
fob
commonli
includ
proxim
distal
airway
secret
collect
via
bronchial
wash
bronchoalveolar
lavag
bal
lung
tissu
via
transbronchi
lung
biopsi
tblb
microbiolog
cytolog
histopatholog
studi
bal
tblb
perform
primari
sourc
diagnost
inform
obtain
via
fob
sign
symptom
warrant
consider
diagnost
fob
includ
fever
leukocytosi
hypoxemia
hemoptysi
unexplain
dyspnea
usual
associ
new
parenchym
opac
see
tabl
immedi
period
recognit
symptom
may
critic
window
lung
sampl
highrisk
patient
includ
fn
earli
posthct
present
acut
multifoc
diffus
infiltr
etiolog
pulmonari
embol
cardiac
abnorm
nonparenchym
infecti
sourc
rule
appropri
fob
consid
promptli
empir
therapi
may
warrant
unstabl
patient
stabl
highrisk
patient
bronchoscopi
perform
urgent
howev
initi
treatment
preclud
continu
risk
assess
proceed
fob
time
manner
see
fig
complic
associ
fob
hm
hct
patient
similar
gener
popul
includ
hypoxemia
bleed
bronchospasm
pneumothorax
cardiac
event
accordingli
contraind
procedur
includ
sever
hypoxemia
myocardi
ischemia
hemodynam
instabl
sever
thrombocytopenia
coagulopathi
bleed
common
complic
hm
hct
subject
set
preval
cytopenia
report
hct
subject
undergo
diagnost
fob
lower
platelet
threshold
bal
exampl
associ
mild
bleed
episod
commonli
use
cutoff
perform
bal
institut
hypoxemia
anoth
major
concern
patient
mani
diminish
pulmonari
reserv
fob
singlecent
retrospect
studi
hct
recipi
procedur
associ
respiratori
declin
mortal
given
likelihood
intub
fob
hct
recipi
acut
respiratori
failur
may
greater
clinician
may
favor
pure
noninvas
diagnost
approach
pc
diagnosi
howev
data
larg
cohort
hct
patient
show
hypoxemia
associ
fob
occur
small
minor
led
mechan
ventil
group
overal
low
rate
intub
hct
neutropen
patient
suggest
low
incid
procedurerel
hypoxemia
may
accept
risk
practic
myriad
challeng
face
provid
determin
appropri
time
fob
hm
hct
patient
mani
sick
undergo
consciou
sedat
gener
anesthesia
diagnost
procedur
provid
prefer
also
shown
barrier
fob
independ
clinic
statu
delay
diagnosi
may
less
respiratori
statu
physician
choic
base
autopsi
studi
pc
diagnos
remain
elus
death
mani
hct
subject
suggest
wait
see
approach
empir
therapi
use
commonli
result
differ
rigor
studi
difficult
limit
prospect
evid
base
decis
regard
optim
time
modal
yield
impact
fob
outcom
popul
avail
literatur
regard
role
diagnost
bronchoscopi
transplant
recipi
review
detail
previous
summar
briefli
herein
yield
time
fiberopt
bronchoscopi
diagnost
yield
commonli
refer
identif
caus
organ
etiolog
bal
protect
brush
specimen
routin
use
hm
hct
patient
andor
tblb
specimen
use
mostli
retrospect
data
overal
rang
yield
fob
hm
hct
wide
diagnost
yield
may
correl
anatom
locat
radiograph
pattern
exampl
bal
return
set
reticularnodular
infiltr
gener
lower
compar
bal
perform
region
hazi
ground
glass
consolid
fob
yield
may
highest
multifoc
infect
p
jirovecii
pneumonia
lowest
mycobacteri
fungal
etiolog
diagnost
yield
may
also
higher
febril
symptomat
patient
compar
asymptomat
retrospect
review
nonintub
allogen
hct
recipi
new
pulmonari
infiltr
first
day
hct
diagnost
yield
fob
doubl
first
day
symptom
onset
studi
show
diagnost
yield
perform
within
hour
initi
antimicrobi
studi
suggest
optim
yield
still
achiev
fob
perform
within
day
initi
therapi
empir
antimicrobi
therapi
lung
sampl
unavoid
realiti
mani
highrisk
patient
may
reduc
diagnost
yield
invas
fungal
diseas
particular
accordingli
yield
diagnost
fob
may
least
patient
would
greatli
benefit
earli
treatment
guidanc
includ
critic
ill
hct
recipi
acut
graftversushost
diseas
import
diagnost
yield
lie
direct
impact
manag
indirect
impact
pcrelat
outcom
mortal
although
studi
rigor
evalu
impact
fob
patient
manag
mortal
use
prospect
method
avail
data
suggest
earli
fob
like
provid
diagnosi
especi
bacteri
upon
chang
manag
made
fobguid
chang
antimicrobi
therapi
report
hm
hct
recipi
includ
withdraw
antimicrobi
agent
nearli
onehalf
hct
subject
fob
result
may
also
provid
critic
insight
manag
resist
pathogen
studi
pathogen
detect
bal
alon
demonstr
antimicrobi
resist
profil
integr
manag
thu
render
inappropri
choic
empir
therapi
base
antimicrobi
profil
identifi
upper
respiratori
peripher
specimen
howev
diagnost
yield
may
alway
correl
chang
manag
demonstr
neutropen
intens
care
unit
patient
diagnost
yield
littl
impact
treatment
chang
impact
diagnost
fob
pcrelat
surviv
also
unclear
sever
retrospect
singlecent
studi
suggest
fob
discern
influenc
mortal
although
prospect
multicent
studi
critic
ill
cancer
patient
includ
subset
hct
recipi
find
fob
influenc
mortal
fob
perform
within
day
symptom
onset
associ
signific
surviv
advantag
day
compar
subject
underw
late
fobassoci
antibiot
chang
anoth
studi
show
fobdriven
chang
antimicrobi
manag
within
day
present
associ
lower
mortal
compar
patient
chang
institut
beyond
week
thu
inabl
target
treatment
expedi
may
contribut
poor
outcom
diagnost
delay
lack
diagnosi
shown
independ
predict
death
immunosuppress
host
pulmonari
infiltr
highest
critic
ill
hct
recipi
fn
find
highlight
import
obtain
correct
microbiolog
diagnosi
compromis
patient
possibl
recommend
approach
diagnost
fiberopt
bronchoscopi
guid
principl
diagnost
fob
consid
hm
hct
subject
upon
present
new
infiltr
diagnost
chest
imag
andor
absenc
clinic
radiograph
respons
least
hour
empir
antimicrobi
therapi
see
fig
event
empir
therapi
institut
sampl
whether
base
acuiti
patient
ill
high
suspicion
opportunist
ill
time
investig
critic
optim
yield
avoid
mask
partial
treat
infect
clinic
decis
observ
effect
empir
therapi
lung
sampl
period
limit
day
use
systemat
institut
protocol
fob
compromis
host
may
consid
controversi
regard
use
lung
biopsi
hm
hct
subject
provid
bal
histor
consid
suffici
diagnosi
other
improv
yield
combin
bal
tblb
compar
bal
alon
also
justifi
low
report
complic
rate
recent
metaanalysi
similar
rate
diagnosi
found
studi
bal
lung
biopsi
hct
recipi
although
infect
identifi
commonli
bal
noninfecti
etiolog
pick
biopsi
upon
suspicion
invas
fungal
viral
infect
howev
tblb
may
improv
diagnost
yield
bal
alon
overal
howev
impact
tblb
manag
remain
unclear
altern
tblb
ctguid
transthorac
lung
biopsi
may
prefer
sampl
peripher
lung
lesion
unless
bal
would
contributori
high
yield
hm
hct
patient
specif
diagnosi
invas
fungal
diseas
use
ctguid
sampl
report
increas
risk
pneumothorax
use
approach
compar
tblb
thu
import
choos
larg
enough
nodul
improv
sampl
yield
face
elev
procedur
risk
surgic
lung
biopsi
slb
whether
open
video
assist
gener
kept
last
resort
owe
increas
procedur
risk
although
tblb
transthorac
lung
biopsi
slb
compar
head
head
decis
proceed
slb
gener
follow
nondiagnost
tblb
unrel
cours
despit
empir
therapi
retrospect
studi
institut
open
lung
biopsi
hm
subject
demonstr
specif
diagnosi
led
chang
manag
correl
improv
overal
surviv
although
diagnost
yield
slb
high
impact
manag
difficult
ascertain
associ
mortal
limit
slb
firstlin
diagnost
modal
transplant
recipi
furthermor
slb
decreas
recent
year
diagnost
invas
fungal
diseas
improv
diagnost
test
lung
specimen
tabl
summar
applic
assay
lung
specimen
diagnosi
infecti
pc
culturedepend
independ
method
identifi
common
respiratori
pathogen
opportunist
organ
bronchoscop
specimen
similar
appli
upper
respiratori
specimen
howev
interpret
requir
caution
contamin
lrt
specimen
oral
upper
airway
flora
colon
need
consid
interpret
result
microbiolog
investig
bal
furthermor
identif
potenti
pathogen
cytomegaloviru
methicillinresist
staphylococcu
aureu
fungal
antigen
betad
glucan
bal
alway
impli
causat
emphas
import
clinic
context
interpret
result
bal
cytolog
continu
use
suggest
process
involv
tissu
invas
p
jirovecii
pneumonia
cytomegaloviru
diseas
absenc
biopsi
specimen
may
also
identifi
malign
cell
eg
lymphoma
hemorrhag
alveolar
proteinosi
bal
cell
count
gener
nonspecif
although
may
use
diffus
alveolar
hemorrhag
organ
pneumonia
lung
tissu
histopatholog
import
definit
diagnosi
invas
fungal
viral
infect
also
malign
organ
pneumonia
interstiti
diseas
associ
drug
toxic
earli
diagnosi
pc
challeng
owe
heterogen
patient
clinic
provid
factor
delay
pc
diagnosi
limit
opportun
target
treatment
may
contribut
poor
outcom
thu
integr
clinicoradiolog
approach
provid
crucial
insight
natur
pc
provid
guidanc
diagnost
test
hm
hct
patient
although
controversi
persist
avail
data
suggest
advantag
earli
fob
term
diagnost
yield
target
manag
mortal
highrisk
hm
hct
recipi
perhap
except
critic
ill
popul
low
threshold
minim
invas
lung
sampl
therefor
guid
principl
highrisk
patient
includ
fn
recipi
hct
practic
may
becom
especi
import
advanc
made
sensit
specif
nextgener
sequenc
applic
infecti
diseas
diagnosi
empir
treatment
import
neutropen
febril
patient
present
sign
symptom
pneumonia
howev
fob
within
hour
intub
empir
treatment
nonetheless
encourag
care
assess
risk
lung
biopsi
via
tblb
transthorac
lung
biopsi
consid
concern
invas
fungal
viral
diseas
absenc
support
data
noninvas
sourc
slb
reserv
case
diagnos
remain
elus
despit
investig
bal
lung
tissu
obtain
via
minim
invas
modal
increas
procedur
risk
warrant
favor
diagnost
result
would
impact
key
aspect
manag
although
prospect
studi
need
determin
optim
strategi
lung
sampl
close
attent
individu
riskbenefit
profil
alway
remain
integr
manag
